Towa Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4553.T

Towa Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) on February 07, 2025: 0.63

Towa Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) is 0.63 on February 07, 2025, a 11.46% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Towa Pharmaceutical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 0.70 on September 26, 2024, which is 12.24% above the current Price to Sales Ratio (P/S).
Towa Pharmaceutical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 0.55 on February 09, 2024, which is -11.95% below the current Price to Sales Ratio (P/S).
Towa Pharmaceutical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 0.62.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 4553.T

Towa Pharmaceutical Co., Ltd.

CEO	Mr. Itsuro Yoshida
IPO Date	April 5, 2004
Location	Japan
Headquarters	2-11, Shinbashi-cho
Employees	4,588
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Personal Care

Description

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

Key trends

Past 5 years